Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
-
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
-
Monte Rosa Therapeutics Announces First Subjects Dosed in P1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader
-
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
-
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inf
-
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
-
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025
-
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results
-
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025